Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

June
09
2026

Is There an Alternative to Mohs Surgery for Non-Melanoma Skin Cancer?

Receiving a non-melanoma skin cancer diagnosis can feel stressful. In fact, studies show that more than one in three patients find the diagnosis traumatic, with many more experiencing anxiety about what comes next. For many,…

December
01
2021

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System

Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date] BOCA RATON, Fla, Dec. 01, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly…

November
22
2021

Treatment for Squamous Cell Carcinoma

Squamous cell carcinoma is a common form of skin cancer that develops in the squamous cells that make up the middle and outer layers of the skin. Though usually not life-threatening, this cancer can be…

November
04
2021

Sensus Healthcare Reports Third Quarter 2021 Financial Results

Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago Affirms expectations for continued growth in 4Q and full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA…

October
20
2021

Sensus Healthcare to Host Third Quarter 2021 Financial Results and Business Update Conference Call on November 4, 2021

BOCA RATON, Fla, Oct. 20, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference…

Archives
Archives

IN THE NEWS

From Scalpel to SRT: Impact of Innovation on the Dermatology Industry